Get informed when a big investor buys or sells
+ FollowOctober 27, 2026 - AI Summary
Overvalued by 29.8% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $17.76 Billion |
|---|---|
| Enterprise Value | $32.90 Billion |
| Earnings per Share | $1.39 |
| Beta | 0.29 |
| Outstanding Shares | 347,798,875 |
| P/E Ratio | 24.79 |
|---|---|
| PEG | -13.68 |
| Price to Sales | 0.56 |
| Price to Book Ratio | 0.39 |
| Enterprise Value to Revenue | 1.03 |
| Enterprise Value to EBIT | 3.26 |
| Enterprise Value to Net Income | 4 |
| Total Debt to Enterprise | 0.49 |
| Debt to Equity | 0.36 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. Its primary therapeutic ...